Outcomes of patients with stage III non-small cell lung cancer (NSCLC) that harbor a mutation.

Background: mutation ( ) in patients (pts) with stage IV non-small cell lung cancer (NSCLC) is associated with inferior survival and poor response to immune checkpoint inhibitors (ICI). The significance of in stage III NSCLC pts treated with concurrent chemoradiation (CCRT) with or without consolidation ICI is unknown.

Methods: Stage III NSCLC patients who received CCRT and had known mutational status were included in this retrospective study.